Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.79 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 4/20 | 0.67 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10114167 | 0.91 | GAA (0.84) | RXFP1GAATHRBTP53TRPA1 | |
| SCHEMBL10114655 | 0.88 | RXFP1 (0.81) | RXFP1GAATHRBTP53TRPA1 | |
| SCHEMBL10114480 | 0.88 | RXFP1 (0.80) | RXFP1GAATHRBTP53TRPA1 | |
| SCHEMBL10114196 | 0.88 | RXFP1 (0.79) | RXFP1GAATHRBTP53TRPA1 | |
| SCHEMBL14754391 | 0.88 | THRB (0.80) | RXFP1GAATHRBTP53TRPA1 | |
| SCHEMBL4533692 | 0.87 | RXFP1 (0.78) | RXFP1GAATHRBTP53TRPA1 | |
| SCHEMBL10114140 | 0.86 | RXFP1 (0.76) | RXFP1GAATHRBTP53TRPA1 | |
| SCHEMBL12260299 | 0.86 | RXFP1 (0.76) | RXFP1GAATHRBTP53TRPA1 | |
| SCHEMBL18166574 | 0.86 | RXFP1 (0.76) | RXFP1GAATHRBTP53TRPA1 | |
| SCHEMBL20079785 | 0.86 | RXFP1 (0.76) | RXFP1GAATHRBTP53TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-3184527-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | Hydra Biosciences, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2170309-B1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | HYDRA BIOSCIENCES INC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20140221401-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221401-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130303521-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-8389529-B2 | Methods and compositions for treating asthma | HYDRA BIOSCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389529-B2 | Methods and compositions for treating asthma | HYDRA BIOSCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8178542-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178542-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110151018-A1 | METHODS OF INSECT CONTROL | BRANDEIS UNIVERSITY (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110151018-A1 | METHODS OF INSECT CONTROL | BRANDEIS UNIVERSITY (US) | 2011-06-23 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110151018-A1 | METHODS OF INSECT CONTROL | TRPA1, TRPV1, TRPV2 | RXFP1 2802/4885GAA 4180/4885THRB 2238/4885 |
| US-20130303521-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | RXFP1 3119/4885GAA 1962/4885THRB 4543/4885 |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | RXFP1 611/4885GAA 876/4885THRB 4409/4885 |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | TRPA1, TRPV1, TRPV2 | RXFP1 33/4885GAA 2708/4885THRB 1242/4885 |
| US-20140221401-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | RXFP1 611/4885GAA 876/4885THRB 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.